Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis

Published:2022-05-10 Issue:6 Volume:24 Page:667-676
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J of Clinical Hypertension

Author:

Wu Hongxiao¹,Ding Xiaoyan¹,Zhang Yongchao¹,Li Wei¹,Chen Jinglong¹

Affiliation:

1. Cancer Center Beijing Ditan Hospital Capital Medical University Beijing China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.14463

Reference40 articles.

1. Global Cancer Observatory. 2021 Cancer IAfRo

2. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients

3. Lenvatinib versus sorafenib as first‐line therapy of advanced hepatocellular carcinoma: a systematic review and meta‐analysis;Facciorusso A;Am J Transl Res

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

5. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected;Cancer;2024-01-27

2. Evaluation of Apatinib-Related Hypertension and Identification of Clinical Risk Factors;Journal of Clinical Pharmacy and Therapeutics;2024-01-25

3. Convexal subarachnoid haemorrhage in a patient under pembrolizumab-lenvatinib combination therapy;BMJ Case Reports;2023-12

4. Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma;Pakistan Journal of Medical Sciences;2023-09-11

5. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice;European Thyroid Journal;2023-07-10